3,955
Views
6
CrossRef citations to date
0
Altmetric
Short Communication

Oral bioavailability and pharmacokinetics of sildenafil citrate dry foam tablets in rats

, , , , , , & | (Reviewing editor) show all
Article: 1510821 | Received 09 May 2018, Accepted 08 Aug 2018, Published online: 27 Aug 2018

References

  • Adena, S. K. R., Viswanadh, M. K., Krishna, P. R., & Induri, A. (2016). Formulation and evaluation of sildenafil citrate fast dissolving tablets using crospovidone and croscarmellose sodium superdisintegrants. Journal of Pharmacy Research, 10(7), 484–492.
  • Ahn, C. Y., Bae, S. K., Bae, S. H., Kang, H. E., Kim, S. H., Lee, M. G., & Shin, W. G. (2011). Pharmacokinetics of sildenafil and its metabolite, N-desmethylsildenafil, in rats with liver cirrhosis and diabetes mellitus, alone and in combination. Xenobiotica, 41(2), 164–174. doi:10.3109/00498254.2010.532885
  • Alkharfy, K. M. (2009). Simple and sensitive LC-ESI-MS method for the quantitation of sildenafil in plasma samples. Journal of Separation Science, 32(22), 3866–3870. doi:10.1002/jssc.200900469
  • Chocalingam, A., Gnanavelu, G., Venkatesan, S., Elangovan, S., Jagannathan, V., Subramaniam, T., … Dorairajan, S. (2005). Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. International Journal of Cardiology, 99(1), 91–95. doi:10.1016/j.ijcard.2003.12.023
  • Degim, I. T., Tugcu-Demiröz, F., Tamer-Ílbasmi§, S., & Acartürk, F. (2008). Development of controlled release sildenafil formulations for vaginal administration. Drug Delivery, 15(4), 259–265. doi:10.1080/10717540802006781
  • Dischinger, A., Page, S., & Kleinebudde, P. (2015). Fast dissolving fillers in dry foam formulation. Powder Technology, 270, 494–501. doi:10.1016/j.powtec.2014.06.036
  • Ghofrani, H. A., Osterloh, I. H., & Grimminger, F. (2006). Sildenafil: From angina to erectile dysfunction to pulmonary hypertension and beyond. Nature Review Drug Discovery, 5(8), 689–702. doi:10.1038/nrd2030
  • Jung, S., Seo, Y., Kim, G. K., Woo, J. S., Yong, C. S., & Choi, H. (2011). Comparison of solubility and pharmacokinetics of sildenafil salts. Archives Pharmacol Research, 34(3), 451–454. doi:10.1007/s12272-011-0313-y
  • Khadka, P., Ro, J., Kim, H., Kim, I., Kim, J., Kim, H., … Lee, J. (2014). Pharmaceutical particle technologies: An approach to improve drug solubility, dissolution and bioavailability. Asian Journal of Pharmaceutical Sciences, 9, 304–316. doi:10.1016/j.ajps.2014.05.005
  • Khan, A. B., Kingsley, T., & Caroline, P. (2017). Sublingual tablets and the benefits of the sublingual route of administration. Journal of Pharmaceutical Research, 16(3), 257–267. doi:10.18579/jpcrkc/2017/16/3/118766
  • Lenz, E., Sprunk, A., Kleinebudde, P., & Page, S. (2015). Impact of fillers on dissolution kinetic of fenofibrate dry foams. Pharmaceutical Development and Technology, 20(5), 570–578. doi:10.3109/10837450.2014.908301
  • Nichols, D.J, Muirhead, G.J, & Harness, J.A. (2002). Pharmacokinetics of sildenafil citrate after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. British Journal of Clinical Pharmacology, 53 (Suppl1), 5s-12s. doi: 10.1046/j.0306-5251.2001.00027.x
  • Ramirez, E., Laosa, O., Guerra, P., Duque, B., Mosquera, B., Borobia, A. M., … Frias, J. (2010). Acceptability and characteristics of 124 human bioequivalence studies with active substances classified according to the biopharmaceutic classification system. British Journal of Clinical Pharmacology, 70(5), 694–702. doi:10.1111/j.1365-2125.2010.03757.x
  • Sawatdee, S., Atipairin, A., Sae Yoon, A., Srichana, T., & Changsan, N. (2017). Enhanced dissolution of sildenafil citrate as dry foam tablets. Pharmaceutical Development and Technology, In press. doi:10.1080/10837450.2017.1281952
  • Sawatdee, S., Atipairin, A., SaeYoon, A., & Srichana, T. (2016). Enhanced dissolution of sildenafil dry foam tablet. Asian Journal of Pharmaceutical Sciences, 11, 191–192. doi:10.1016/j.ajps.2015.11.042
  • Sawatdee, S., Hiranphan, P., Laphanayos, K., & Srichana, T. (2013). Evaluation of sildenafil pressurized metered dose inhalers as a vasodilator in umbilical blood vessels of chicken egg embryos. European Journal of Pharmaceutics and Biopharmaceutics, 86(1), 90–97. doi:10.1016/j.ejpb.2013.09.001
  • Sheu, M., Hsieh, C., Chen, R., Chou, P., & Ho, H. (2016). Rapid-onset sildenafil sublingual drug delivery systems: In vitro evaluation and in vivo pharmacokinetic studies in rabbits. Journal of Pharmaceutical Sciences, 105(9), 2774–2781. doi:10.1016/j.xphs.2016.01.015
  • Shin, H. S., Bae, S. K., & Lee, M. G. (2006). Pharmacokinetics of sildenafil after intravenous and oral administration in rats: Hepatic and intestinal first-pass effects. International Journal of Pharmaceutics, 320(1–2), 64–70. doi:10.1016/j.ijpharm.2006.04.005
  • Sprunk, A., Page, S., & Kleinebudde, P. (2013). Influence of process parameters and equipment on dry foam formulation properties using indomethacin as model drug. International Journal of Pharmaceutics, 455(1–2), 189–196. doi:10.1016/j.ijpharm.2013.07.039
  • Thompson, M. R., Weatherley, S., Pukadyil, R. N., & Sheskey, P. J. (2012). Foam granulation: New developments in pharmaceutical solid oral dosage forms using twin screw extrusion machinery. Drug Development and Industrial Pharmacy, 38(7), 771–784. doi:10.3109/03639045.2011.633265
  • Tripathi, A. S., Mazumder, P. M., & Chandewar, A. V. (2014). Changes in the pharmacokinetic of sildenafil citrate in rats with Streptozotocin-induced diabetic nephropathy. Journal of Diabetes and Metabolic Disorders, 13(1), 1–4. doi:10.1186/2251-6581-13-8
  • Walker, D. K., Ackland, M. J., James, G. C., Muiehead, G. J., Rance, D. J., Wastall, P., & Wright, P. A. (1999). Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica, 29(3), 297–310. doi:10.1080/004982599238687
  • Zayed, R., Kamel, A. O., Shukr, M., & El-Shamy, A. E. (2012). An in vitro and in vivo comparative study of directly compressed solid dispersions and freeze dried sildenafil citrate sublingual tablets for management of pulmonary arterial hypertension. Acta Pharmaceutica, 62(3), 411–432. doi:10.2478/v10007-012-0027-9